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2Dear Sir, 
According to World Health Organization (WHO), the incidence
ate of tuberculosis (TB) in Iran has decreased from 36/10 0,0 0 0
n 1990 to 17/10 0,0 0 0 in 2014 [1] . The main tasks performed by
inistry of Health of Iran for decreasing the incidence rate of TB,
specially in the last three decades include: starting the BCG vac-
ination in 1984, establishment of National TB Programme (NTP)
n 1996, conducting the Directly Observed Treatment, Short-Course
DOTS) strategy in 1997, performing TB control program in pris-
ns in 2002, using the electronic system for TB reporting in 2003,
stablishment of seven regional TB laboratories in the country dur-
ng 2010–2013 and free access to TB medication. However, one of
he important challenges for TB control strategies include the in-
reasing prevalence and rapid distribution of multidrug-resistant
B (MDR-TB) in Iran. Recently, this concern has been further in-
ensiﬁed by reports of extensively drug resistant (XDR) – and to-
ally drug resistant-TB (TDR-TB) [2] . According to the Iranian centre
or disease control and prevention, the number of conﬁrmed MDR-
B cases has increased from 8 in 2003 to 41 in 2015 [3] . Gener-
lly, patients infected with drug resistant strains of Mycobacterium
uberculosis need a long-term treatment and drugs with a higher
ost; the treatment cost proportion of Iranian MDR-TB patients to
rug-sensitive cases is roughly as 15,0 0 0–80,0 0 0 to 150 dollars;
he course of treatment proportion, 18–24 to 6 months; and hos-
italization rate proportion, 100 to 10 [3] . The increased preva-
ence of MDR-TB in Iran may have several reasons. Iran is an east-
rn Mediterranean country that located between the high MDR-
B (Pakistan, Azerbaijan and Armenia) and high-TB burden (Pak-
stan and Afghanistan) countries in the region. Based on the Ira-
ian centre for disease control and prevention, high rate of drug-
esistant cases was seen in border provinces of Iran i.e. Sistan–
aluchestan, Khorasan-Razavi, Golestan and East-Azerbaijan [2] .
istan-Baluchestan and Khorasan-Razavi are densely populated and
eriously affected in terms of economy and public health status.
dditionally, long borders (1500 km) with Afghanistan and Pak-
stan, have made these provinces a natural route for TB transmis-
ion. Regional laboratories with drug susceptibility testing capabil-
ty in these regions are still under quality control and do not have
roper facilities for patients admission. Consequently, local and im-
igrant patients with MDR-TB have to come to the central lab-
ratory for further treatment and hospitalization, which may in-
rease the risk of MDR-TB transmission in the country. Further-ttp://dx.doi.org/10.1016/j.jctube.2016.11.004 
405-5794/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uore, prescription of inadequate treatment regimen, irregular drug
upply and poor drug quality have also been recently recognized
s other important risk factors for emergence of MDR-TB in Iran.
n addition to the above reasons, establishment of the nationwide
nternet-based reporting system may also have a role for the ob-
erved prevalence of MDR-TB. The ministry, set up a regulation re-
uiring all hospitals to report and refer suspected MDR-TB cases
o the national central laboratory for further investigation. As a re-
ult, the number of these cases and suspected cases reported by
ational laboratory has increased [3] . The development of better
nd more rapid diagnostic methods and continuous monitoring of
rug resistance are urgent priorities for the containment of MDR-
B in Iran. 
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